Anavex Life Sciences to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference
September 26 2018 - 06:00AM
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:
AVXL), a clinical-stage biopharmaceutical company developing
differentiated therapeutics for the treatment of neurodegenerative
and neurodevelopmental diseases including Alzheimer’s disease, Rett
syndrome and other central nervous system (CNS) diseases, today
announced that Christopher U. Missling, PhD, President and Chief
Executive Officer of Anavex, will present at the Cantor Fitzgerald
Global Healthcare Conference at the InterContinental New York
Barclay in New York City on October 3, 2018 at 2:50 p.m. eastern
time.
A live audio webcast of the presentation will be available
at http://wsw.com/webcast/cantor7/avxl/. A replay will be
available at www.anavex.com and will be accessible for three
months following the presentation.
About ANAVEX®2-73
ANAVEX®2-73 activates the Sigma-1 receptor (S1R)
protein, which serves as a molecular chaperone and functional
modulator involved in restoring homeostasis. S1R activation has
demonstrated ability to reduce key pathophysiological signs of
Alzheimer’s disease: beta amyloid, hyperphosphorylated tau, and
increased inflammation. In a Phase 2a Alzheimer’s disease study,
ANAVEX®2-73 has shown dose dependent improvement in exploratory
endpoints of cognition (MMSE) and function (ADCS-ADL). Whole DNA
Exome Sequencing (WES) and RNA expression genomic analysis of
ANAVEX®2-73 Phase 2a Alzheimer’s disease patients was performed.
The ANAVEX®2-73 Phase 2b/3 study design includes genomic precision
medicine biomarkers identified in the ANAVEX®2-73 Phase 2a
study.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a
publicly traded biopharmaceutical company dedicated to the
development of differentiated therapeutics for the treatment of
neurodegenerative and neurodevelopmental diseases including
Alzheimer’s disease, other central nervous system (CNS) diseases,
pain and various types of cancer. Anavex’s lead drug candidate,
ANAVEX®2-73, recently completed a successful Phase 2a clinical
trial for Alzheimer’s disease. ANAVEX®2-73 is an orally available
drug candidate that restores cellular homeostasis by targeting
sigma-1 and muscarinic receptors. Preclinical studies demonstrated
its potential to halt and/or reverse the course of Alzheimer’s
disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic,
neuroprotective and anti-depressant properties in animal models,
indicating its potential to treat additional CNS disorders,
including epilepsy. The Michael J. Fox Foundation for Parkinson’s
Research previously awarded Anavex a research grant, which fully
funded a preclinical study to develop ANAVEX®2-73 for the treatment
of Parkinson’s disease. ANAVEX®3-71, which targets sigma-1 and M1
muscarinic receptors, is a promising preclinical drug candidate
demonstrating disease-modifying activity against the major
hallmarks of Alzheimer’s disease in transgenic (3xTg-AD) mice,
including cognitive deficits, amyloid and tau pathologies. In
preclinical trials, ANAVEX®3-71 has shown beneficial effects on
neuroinflammation and mitochondrial dysfunction. Further
information is available at www.anavex.com. You can also connect
with the company
on Twitter, Facebook and LinkedIn.
Forward-Looking Statements
Statements in this press release that are not
strictly historical in nature are forward-looking statements. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties.
Actual events or results may differ materially from those projected
in any of such statements due to various factors, including the
risks set forth in the Company’s most recent Annual Report on Form
10-K filed with the SEC. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. All forward-looking statements are qualified in
their entirety by this cautionary statement and Anavex Life
Sciences Corp. undertakes no obligation to revise or update this
press release to reflect events or circumstances after the date
hereof.
For Further Information:
Anavex Life Sciences Corp.Research &
Business DevelopmentToll-free: 1-844-689-3939Email:
info@anavex.com
Investors & Media:Scott
GordonCore IRscottg@coreir.com
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Feb 2024 to Mar 2024
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Mar 2023 to Mar 2024